Jeffrey W. Sherman Sells 5,187 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP) Stock

Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) EVP Jeffrey W. Sherman sold 5,187 shares of the stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $113.29, for a total value of $587,635.23. Following the completion of the transaction, the executive vice president now owns 49,314 shares of the company’s stock, valued at $5,586,783.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Horizon Therapeutics Public Stock Down 0.2 %

HZNP opened at $113.00 on Friday. The business’s 50-day simple moving average is $94.08 and its 200-day simple moving average is $78.21. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.74 and a current ratio of 3.96. Horizon Therapeutics Public Limited has a one year low of $57.84 and a one year high of $117.49. The stock has a market capitalization of $25.61 billion, a P/E ratio of 46.31, a price-to-earnings-growth ratio of 1.74 and a beta of 1.16.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last posted its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.25. Horizon Therapeutics Public had a return on equity of 24.59% and a net margin of 15.51%. The business had revenue of $925.36 million for the quarter, compared to analysts’ expectations of $888.93 million. Analysts anticipate that Horizon Therapeutics Public Limited will post 4.23 EPS for the current year.

Institutional Trading of Horizon Therapeutics Public

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Lebenthal Global Advisors LLC grew its holdings in shares of Horizon Therapeutics Public by 5.8% during the second quarter. Lebenthal Global Advisors LLC now owns 2,669 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 147 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Horizon Therapeutics Public by 0.3% during the second quarter. Arizona State Retirement System now owns 60,139 shares of the biopharmaceutical company’s stock worth $4,797,000 after buying an additional 158 shares during the last quarter. Aspire Private Capital LLC grew its holdings in shares of Horizon Therapeutics Public by 2.3% during the second quarter. Aspire Private Capital LLC now owns 7,082 shares of the biopharmaceutical company’s stock worth $565,000 after buying an additional 158 shares during the last quarter. Xponance Inc. grew its holdings in shares of Horizon Therapeutics Public by 0.6% during the third quarter. Xponance Inc. now owns 24,998 shares of the biopharmaceutical company’s stock worth $1,547,000 after buying an additional 160 shares during the last quarter. Finally, Quent Capital LLC grew its holdings in shares of Horizon Therapeutics Public by 8.8% during the third quarter. Quent Capital LLC now owns 1,969 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 160 shares during the last quarter. Institutional investors and hedge funds own 91.01% of the company’s stock.

Wall Street Analyst Weigh In

HZNP has been the subject of several analyst reports. StockNews.com upgraded Horizon Therapeutics Public from a “hold” rating to a “buy” rating in a research report on Thursday, November 3rd. TheStreet upgraded Horizon Therapeutics Public from a “c+” rating to a “b-” rating in a research report on Tuesday, November 22nd. Guggenheim lowered Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and raised their price target for the stock from $98.00 to $116.50 in a research report on Tuesday, December 13th. Jefferies Financial Group lifted their target price on Horizon Therapeutics Public from $101.00 to $125.00 in a report on Thursday, December 1st. Finally, Wells Fargo & Company lowered Horizon Therapeutics Public from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $118.00 to $116.50 in a report on Monday, December 12th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $111.42.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.